Hong Kong Stock Movement: Hengrui Pharma (01276) Rises Over 3% as Self-Developed Alzheimer's Drug SHR-3201 Injection Approved for Clinical Trials

Stock News10-15

Hong Kong Stock Movement: Hengrui Pharma (01276) rose over 3%, reaching 2.97% higher at HK$47.8 as of press time, with a turnover of HK$41.3491 million.

On the news front, Hengrui Pharma issued an announcement stating that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and clinical trials will be initiated in the near future.

SHR-3201 Injection is a self-developed drug by the company for the treatment of Alzheimer's disease (AD), capable of clearing disease biomarkers in patients' brains and delaying cognitive decline. According to inquiries, no similar drugs have been approved for marketing both domestically and internationally.

As of now, the cumulative R&D investment in the SHR-3201 Injection-related project is approximately 48.8 million yuan (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111412013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-15 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111412013","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement: Hengrui Pharma (01276) Rises Over 3% as Self-Developed Alzheimer's Drug SHR-3201 Injection Approved for Clinical Trials","media":"Stock News","content":"<p>Hong Kong Stock Movement: <b>Hengrui Pharma</b> (<b>01276</b>) rose over 3%, reaching 2.97% higher at HK$47.8 as of press time, with a turnover of HK$41.3491 million.<br><br>On the news front, <b>Hengrui Pharma</b> issued an announcement stating that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and clinical trials will be initiated in the near future.<br><br>SHR-3201 Injection is a self-developed drug by the company for the treatment of Alzheimer's disease (AD), capable of clearing disease biomarkers in patients' brains and delaying cognitive decline. According to inquiries, no similar drugs have been approved for marketing both domestically and internationally.<br><br>As of now, the cumulative R&D investment in the SHR-3201 Injection-related project is approximately 48.8 million yuan (unaudited).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement: Hengrui Pharma (01276) Rises Over 3% as Self-Developed Alzheimer's Drug SHR-3201 Injection Approved for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement: Hengrui Pharma (01276) Rises Over 3% as Self-Developed Alzheimer's Drug SHR-3201 Injection Approved for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-15 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong Stock Movement: <b>Hengrui Pharma</b> (<b>01276</b>) rose over 3%, reaching 2.97% higher at HK$47.8 as of press time, with a turnover of HK$41.3491 million.<br><br>On the news front, <b>Hengrui Pharma</b> issued an announcement stating that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and clinical trials will be initiated in the near future.<br><br>SHR-3201 Injection is a self-developed drug by the company for the treatment of Alzheimer's disease (AD), capable of clearing disease biomarkers in patients' brains and delaying cognitive decline. According to inquiries, no similar drugs have been approved for marketing both domestically and internationally.<br><br>As of now, the cumulative R&D investment in the SHR-3201 Injection-related project is approximately 48.8 million yuan (unaudited).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1111412013","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111412013","pubTimestamp":1792029855,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong Stock Movement: Hengrui Pharma (01276) rose over 3%, reaching 2.97% higher at HK$47.8 as of press time, with a turnover of HK$41.3491 million.On the news front, Hengrui Pharma issued an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0188":"融资融券","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0012":"证金概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0028":"国家队","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","PSYK":"PSYK ETF","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK1191":"制药","MDTX":"Corgi MediaTek 2x Daily ETF","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BMED":"iShares Health Innovation Active ETF","BK0060":"抗癌","BK4588":"碎股","KCAI":"KraneShares China Alpha Index ETF","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK4585":"ETF&股票定投概念","01276":"恒瑞医药","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0196":"行业龙头","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0239":"医药制造","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","VXUS":"国际股票ETF-Vanguard","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","BK0183":"MSCI概念"},"translate_title":"港股异动：自研老年痴呆症药物SHR-3201注射液获批临床试验 恒瑞医药(01276)涨逾3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"IBBQ":1,"PSYK":1,"IBBJ":1,"KCAI":1,"VXUS":1,"BMED":1,"MDTX":1,"01276":1},"content_text":"Hong Kong Stock Movement: Hengrui Pharma (01276) rose over 3%, reaching 2.97% higher at HK$47.8 as of press time, with a turnover of HK$41.3491 million.On the news front, Hengrui Pharma issued an announcement stating that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and clinical trials will be initiated in the near future.SHR-3201 Injection is a self-developed drug by the company for the treatment of Alzheimer's disease (AD), capable of clearing disease biomarkers in patients' brains and delaying cognitive decline. According to inquiries, no similar drugs have been approved for marketing both domestically and internationally.As of now, the cumulative R&D investment in the SHR-3201 Injection-related project is approximately 48.8 million yuan (unaudited).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111412013","isCrawlerRequest":true}